OptiBiotix Health PLC
OPTI
Company Profile
Business description
OptiBiotix Health PLC is engaged in the field of healthcare. As a life science company, its prime focus lies in researching the area of biotechnology. Its activities include the identification of microbial strains, compounds, and formulations for use in food ingredients, supplements, and active compounds that can impact human physiology, deriving potential health benefits. The company derives majority of the revenue from the sale of Functional Fibres. The company markets its products in the United Kingdom under trademark names such as OptiBiotix, SweetBiotix, and SkinBioTherapeutics.
Contact
Innovation Centre, Innovation Way
Heslington
YorkYO10 5DG
GBRT: +44 1904435100
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
10
Stocks News & Analysis
stocks
Chart of the Week: Opportunities with wide-moat retailers
Consumer defensive names look undervalued.
stocks
New ASX share added to our best ideas
Earnings outlook is strong and the shares trade at a discount to our fair value.
stocks
Fair value downgraded for ASX heavyweight
Our capital allocation rating was also lowered due to balance sheet weakness.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,240.30 | 42.60 | 0.46% |
| CAC 40 | 8,075.76 | 108.81 | 1.37% |
| DAX 40 | 24,449.08 | 335.46 | 1.39% |
| Dow JONES (US) | 46,441.10 | 43.21 | 0.09% |
| FTSE 100 | 9,453.25 | 6.82 | 0.07% |
| HKSE | 27,287.12 | 431.56 | 1.61% |
| NASDAQ | 22,755.16 | 95.15 | 0.42% |
| Nikkei 225 | 44,936.73 | 385.88 | 0.87% |
| NZX 50 Index | 13,451.76 | 17.77 | 0.13% |
| S&P 500 | 6,711.20 | 22.74 | 0.34% |
| S&P/ASX 200 | 8,945.90 | 40.10 | 0.45% |
| SSE Composite Index | 3,882.78 | 20.25 | 0.52% |